August 22, 2014 — The Journal of Clinical Psychopharmacology has published a study linking the use of Risperdal (risperidone), a powerful anti-psychotic drug, with a 69% increased risk of gynecomastia (male breast growth) when compared to men not on the drugs.
The analysis was based on data from 8,385 men between the ages of 40-85 who were newly diagnosed with gynecomastia, including 27 cases in men on Risperdal. These cases were matched with 10 controls from the same age group who did not take an anti-psychotic drug. Researchers looked at data between January 2001 and June 2011.
Middle-aged men on Risperdal had a 69% higher rate of gynecomastia. They were also 40-41% more likely to be diagnosed with gynecomastia than men on other anti-psychotics, such as Zyprexa (olanzapine) or Seroquel (quetiapine).
Data from the study was originally presented in March but was not published until this month.
These conclusions corroborate data from the U.S. Food and Drug Administration (FDA), which has received more reports of gynecomastia from Risperdal than any other anti-psychotic. A recent study in the Netherlands also found higher rates of gynecomastia from Risperdal than Seroquel or Zyprexa.
Johnson & Johnson, the manufacturer of Risperdal, is facing hundreds of lawsuits from people who were injured by the drug. Many of these lawsuits were filed by men who were prescribed Risperdal as children and developed gynecomastia in their formative teenage years. These plaintiffs allege that Risperdal caused long-lasting psychological trauma as well as severe physical disfigurement.
Lawsuits also blame Johnson & Johnson for improperly marketing Risperdal in children before it was approved for pediatric purposes. Last year, the Justice Department agreed to a $2.2 billion settlement with the drug-maker for improperly marketing Risperdal and two other drugs.
Do I have a Risperdal Lawsuit?
The Schmidt Firm, PLLC is currently accepting Risperdal induced injury cases in all 50 states. If you or somebody you know has been injured by gynecomastia, you should contact our lawyers immediately for a free case consultation. Please use the form below to contact our Defective Drug Litigation Group or call toll free 24 hours a day at (866) 920-0753.
Attention Lawyers: We consider a referral from another law firm to be one of the greatest compliments. If your firm is interested in referring us a case or for us to send you a list of previous award judgments and/or average referral fees, please visit the Lawyer Referral section of our website.